Microbicides and HIV prevention: lessons from the past, looking to the future
GC Morris, CJN Lacey - Current opinion in infectious diseases, 2010 - journals.lww.com
Development of a protective 'barrier'which can be controlled by the receptive partner
independent of time of coitus remains a key goal in HIV prevention. A gel or ring-delivered …
independent of time of coitus remains a key goal in HIV prevention. A gel or ring-delivered …
[HTML][HTML] Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
AM Conway, GC Morris, S Smith, M Vekeria… - British Journal of …, 2022 - nature.com
Background Many patients referred with a provisional diagnosis of cancer of unknown
primary (pCUP) present with presumed metastatic disease to the liver. Due to the lack of …
primary (pCUP) present with presumed metastatic disease to the liver. Due to the lack of …
[HTML][HTML] Current and emerging strategies for biocompatible materials for implantable electronics
Y Zhou, GHB Morris, M Nair - Cell Reports Physical Science, 2024 - cell.com
The application of electronics to biological systems has rapidly developed over the last
century, facilitating significant advances in the diagnosis and therapy of a large range of …
century, facilitating significant advances in the diagnosis and therapy of a large range of …
Urban geographies of waste
N McClintock, G Morris - Urban Geography, 2024 - Taylor & Francis
Through this virtual collection, we examine how urban geographers have described,
characterized, theorized, and mobilized waste in the pages of Urban Geography since 1990 …
characterized, theorized, and mobilized waste in the pages of Urban Geography since 1990 …
[HTML][HTML] MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide
GC Morris, RC Wiggins, SC Woodhall, JM Bland… - PLoS …, 2014 - journals.plos.org
Background Monoclonal antibodies (mAbs) which potently neutralize a broad range of HIV
isolates are potential microbicide candidates. To date, topical application of mAbs in …
isolates are potential microbicide candidates. To date, topical application of mAbs in …
[HTML][HTML] Comparative immunogenicity of HIV-1 gp140 vaccine delivered by parenteral, and mucosal routes in female volunteers; MUCOVAC2, a randomized two …
CA Cosgrove, CJ Lacey, AV Cope, A Bartolf, G Morris… - PLoS …, 2016 - journals.plos.org
Background Defining optimal routes for induction of mucosal immunity represents an
important research priority for the HIV-1 vaccine field. In particular, it remains unclear …
important research priority for the HIV-1 vaccine field. In particular, it remains unclear …
Benefits and harms of hypertension and high-normal labels: a randomized experiment
Background: Recent US guidelines lowered the threshold for diagnosing hypertension while
other international guidelines use alternative/no labels for the same group (blood pressure …
other international guidelines use alternative/no labels for the same group (blood pressure …
Viricidal Efficacy of a 405‐nm Environmental Decontamination System for Inactivation of Bacteriophage Phi6: Surrogate for SARS‐CoV‐2
LG Sinclair, Z Ilieva, G Morris… - Photochemistry and …, 2023 - Wiley Online Library
The highly transmittable nature of SARS‐CoV‐2 has increased the necessity for novel
strategies to safely decontaminate public areas. This study investigates the efficacy of a low …
strategies to safely decontaminate public areas. This study investigates the efficacy of a low …
A cross-sectional study showing differences in the clinical diagnosis of pelvic inflammatory disease according to the experience of clinicians: implications for training …
GC Morris, CMW Stewart, SA Schoeman… - Sexually transmitted …, 2014 - sti.bmj.com
Objectives Pelvic inflammatory disease (PID) generates diagnostic difficulty even for
experienced doctors. Junior doctors and nurses also assess women with symptoms …
experienced doctors. Junior doctors and nurses also assess women with symptoms …
Outcomes and experiences of using oral voriconazole with or without concomitant topical agents to treat refractory vulvovaginal yeast infections
GC Morris, G Dean, S Soni… - … journal of STD & …, 2022 - journals.sagepub.com
Background We describe 11 cases of refractory vulvovaginal yeast infections (RVVYI)
treated using oral voriconazole with or without concomitant topical agents. Methods …
treated using oral voriconazole with or without concomitant topical agents. Methods …